Middle East and Africa Oligonucleotide Synthesis Market

Middle East and Africa Oligonucleotide Synthesis Market Size & Forecast:

• Middle East and Africa Oligonucleotide Synthesis Market Size 2025: USD 73.49 Million
• Middle East and Africa Oligonucleotide Synthesis Market Size 2033: USD 185.56 Million
• Middle East and Africa Oligonucleotide Synthesis Market CAGR: 12.30%
• Middle East and Africa Oligonucleotide Synthesis Market Segments: By Product (DNA, RNA, Modified), By Application (Research, Diagnostics, Therapeutics, Forensics), By End-User (Pharma, Biotech, Academic Institutes, CROs)

To learn more about this report,  Download Free Sample Report

Middle East and Africa Oligonucleotide Synthesis Market Summary:

The Middle East and Africa Oligonucleotide Synthesis Market size is estimated at USD 73.49 Million in 2025 and is anticipated to reach USD 185.56 Million by 2033, growing at a CAGR of 12.30% from 2026 to 2033. The Middle East and Africa region contains an oligonucleotide synthesis market that includes Saudi Arabia, United Arab Emirates, South Africa and the Rest of Middle East and Africa countries. The life sciences and biotechnology industry will experience its next research and diagnostic phase through molecular tools which scientists will use to conduct their work. Clinical laboratories and academic centers will increase their demand for customized high-purity sequences which they need for their genomic testing operations. Regional laboratories will implement automated synthesis systems to achieve faster results and more consistent outcomes. The Gulf countries will establish new regulations which include more stringent quality requirements that will promote domestic manufacturing collaborations. The changing healthcare needs of the future will drive healthcare providers to adopt nucleic acid-based treatments as standard components of their medical services.

Key Market Trends & Insights:

• The oligonucleotide synthesis market in Saudi Arabia, United Arab Emirates, and South Africa is shifting toward precision medicine, with hospitals and labs demanding clinical-grade, highly accurate genetic sequences for diagnostics and treatment.
• Technological advancements such as automated and miniaturized synthesis platforms, along with cloud-based data integration, will boost production efficiency and help regional players close the gap with global standards.
• Rising expectations in healthcare will drive demand for fast, customized genetic solutions, pushing suppliers to offer flexible, high-quality synthesis services tailored to patient-specific needs.
• Increased investment from pharmaceutical and biotech companies in nucleic acid-based therapies will further accelerate demand for advanced oligonucleotide synthesis capabilities.
• Regulatory frameworks, especially in Saudi Arabia and the UAE, will become more defined around traceability, quality assurance, and global compliance, creating both challenges and opportunities for local and international suppliers.

Middle East and Africa Oligonucleotide Synthesis Market Segmentation

By Product

DNA- The DNA oligonucleotides will serve as the primary component for laboratory procedures throughout the entire region. Research institutions and diagnostic labs will use them to perform sequencing and PCR amplification and gene analysis procedures. The regional healthcare systems will start demanding more precise genomic testing because they develop their genomic testing capabilities. Suppliers will concentrate on achieving higher purity standards and faster delivery times because customers will demand dependable product performance for all their operational needs.

RNA- RNA-based synthesis will gain stronger attention as interest in gene expression studies and RNA-driven therapies increases. Laboratories will seek stable and high-quality RNA sequences which they will use for mRNA research and vaccine development purposes. Handling sensitivity and degradation risks will push vendors to improve storage and transport solutions. Regional biotechnology companies will allocate more funding to RNA technology development which will result in new purchasing methods and the establishment of dedicated manufacturing facilities.

Modified- Modified oligonucleotides will emerge as a key area of differentiation especially for advanced therapeutic and diagnostic use cases. Chemical modifications will enhance stability and binding efficiency and resistance to degradation which makes them suitable for complex biological environments. Pharmaceutical developers will increasingly demand targeted delivery systems which they use to develop their products. Suppliers will increasingly offer customized modifications which allow clients to design sequences that align with specific clinical or experimental requirements.

To learn more about this report,  Download Free Sample Report

By Application

Research- The current research applications will serve as the primary driver for demand at universities and government-funded laboratories. The scientists will use synthesized sequences to perform gene editing and cloning and conduct their molecular biology research. The research activities of Saudi Arabia and South Africa will increase because their funding programs will expand. The research activities will increase because more advanced synthesis methods will be used to achieve exact experimental results.

Diagnostics- The healthcare systems show a strong commitment to implementing early detection methods which will create a fast-growing field of diagnostics that focuses on personalized patient care. Oligonucleotides will serve as essential components in molecular diagnostic kits which detect infectious diseases and perform genetic testing. The laboratories will require their testing results to be completed within a shorter time frame while achieving better test performance. The suppliers will implement this change by adjusting their production methods to meet the needs of clinical settings which require dependable products that meet all regulatory standards for various medical environments.

Therapeutics- The introduction of nucleic acid therapeutic treatments into clinical testing will drive their therapeutic uses to develop at a gradual pace throughout the region. Pharmaceutical companies will develop oligonucleotide-based medications which they will use to create specific treatments for both common medical conditions and rare genetic disorders. The current project needs to obtain high-quality materials through the process of creating large quantities of products. The growing number of clinical trials will lead to stronger partnerships between regional companies and worldwide biotechnology firms which will help build local expertise in producing therapeutic-grade materials.

Forensics- The forensic uses of oligonucleotides will remain relevant but confined to the scope of specialized application within law enforcement agencies and courts. Oligonucleotides will help develop techniques that will be helpful in DNA identification. The governments will continue to make investments in improving their forensic facilities because they will help solve crimes more easily. There will be a need for standardization of techniques as well as use of authentic methods of oligonucleotide synthesis in laboratories.

By End-User

Pharma- Pharmaceutical firms will generate a demand for high-quality scalable oligonucleotide synthesis technologies. The research and development conducted by these companies will focus on creating targeted drugs and using precision medicine methodologies. The demand for a stable supply chain and strict quality control systems is needed by pharmaceutical companies because their drug discovery process requires various products. Firms that offer synthesis services will have to build long-term relationships with the clients that require them for both compliance and development reasons.

Biotech- The region will become innovative through research activities conducted by local biotech companies which will investigate new applications of nucleic acid technology. Small and medium companies will concentrate on exploring different areas such as gene editing, synthetic biology, and RNA technology. Service providers will have to change their technological abilities since their requirements demand flexibility and customization.

Academic Institutes- Academic institutions will remain central to foundational research and talent development. The research centers and universities will conduct their work through oligonucleotides which they will use to teach and test their students and to work on joint research projects. The institutes will acquire advanced equipment and modern technologies because their international partnerships and funding sources will increase. The research needs to focus on producing affordable and dependable solutions which can maintain large research activities while delivering high research standards.

CRO- Contract research organizations will become more important as pharmaceutical and biotech companies increase their outsourcing needs. The organizations will need synthesis services which can operate at both high efficiency and large production capacity to handle multiple client projects at the same time. The decision-making process will focus primarily on two factors, which include speed and cost-effectiveness. The regional CROs will expand their operational capabilities, which will enable them to function as intermediaries who connect global demand with local synthesis providers while enhancing the entire service ecosystem.

Regional Insights

The Kingdom of Saudi Arabia will establish itself as an organized center which provides advanced laboratory services through its ongoing healthcare development programs and national development initiatives. Research centers will expand genomic initiatives, which will increase demand for precise synthesis services. The government will support domestic manufacturing development through its focus on domestic production. The organization will gain technical knowledge through its collaboration with international biotech companies, while public healthcare institutions will follow strict quality standards to make their procurement choices.

The United Arab Emirates will focus on creating healthcare systems that drive innovation through advanced diagnostic technologies and personalized treatment solutions, which will determine their laboratory operational needs. Free zones and research clusters will attract global companies, creating a competitive environment for synthesis providers. The purchasing process will be influenced by three factors, which include the organizations' need for speed and their ability to customize products and their use of digital technology. The existing regulatory framework will improve, which will enable specialized service providers to enter the market while supporting the growth of advanced molecular research facilities.

South Africa will continue to function as a research-driven market because academic institutions and public health programs will provide support for its operations. The laboratories will focus on developing synthesis methods which provide both affordable and dependable results for their research on infectious diseases and chronic diseases. Universities in the local area will establish research partnerships which will connect them with international research organizations. The laboratory system will achieve better operational performance through infrastructure upgrades which will be funded by institutions that use different methods for purchasing and planning their scientific research activities.

The Middle East and Africa region will display different patterns of technology uptake because different countries have different levels of economic development and healthcare infrastructure development. Emerging markets will establish their essential laboratory facilities which will result in increased need for fundamental synthesis operations. International aid and regional collaborations will support knowledge transfer. Over time, rising public knowledge about genetic testing and disease monitoring will lead to increased adoption of these technologies by smaller healthcare systems.

Recent Development News

In January 2026, United Arab Emirates Strengthens Biotech Ecosystem with Steady Growth. The expansion of research clusters and healthcare innovation zones leads to increased adoption of advanced synthesis technologies. The country is focusing on integrating precision medicine into clinical systems, which is driving demand for customized oligonucleotides and reinforcing its role as a regional hub for biotech-driven healthcare solutions.

In June 2025, Regional Momentum Driven by Research and Clinical Expansion. The life sciences industry experiences progress through two main factors which include more clinical trials and increased research work. Countries are witnessing rising adoption of gene-based technologies in diagnostics and therapeutics which is gradually transforming healthcare delivery and creating sustained demand for synthesis services across both emerging and established markets.

Key Middle East and Africa Oligonucleotide Synthesis Market Company Insights

The competitive landscape of the middle east and africa (saudi arabia united arab emirates south africa rest of middle east and africa) oligonucleotide synthesis market will remain shaped by a mix of global biotechnology leaders and regionally expanding service providers. Thermo Fisher Scientific Agilent Technologies Merck KGaA Eurofins Scientific and Twist Bioscience will expand their market presence through new partnerships and establishment of local distribution centers. The companies will develop high-purity synthesis systems which use automated systems to create special solutions that meet present-day clinical and research needs. The market will establish domestic capabilities through its partnerships with local laboratories which will enable knowledge sharing and equipment construction while it continues to depend on international expert resources.

Company List

• Thermo Fisher
• Merck
• Agilent
• Eurofins
• GenScript
• Integrated DNA Technologies
• Bio-Synthesis
• LGC Biosearch
• Twist Bioscience
• Bioneer
• TriLink BioTechnologies
• ATDBio
• Microsynth
• Sigma-Aldrich
• Bio Basic

Middle East and Africa Oligonucleotide Synthesis Market Report Segmentation

By Product

• DNA
• RNA
• Modified

By Application

• Research
• Diagnostics
• Therapeutics
• Forensics

By End-User

• Pharma
• Biotech
• Academic Institutes
• CROs